Detalles de la búsqueda
1.
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
Br J Haematol
; 155(5): 580-7, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21950583
2.
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
Am J Hematol
; 86(1): 25-30, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21120861
3.
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Ann Hematol
; 87(8): 623-31, 2008 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-18463870
4.
Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis.
J Clin Oncol
; 21(22): 4239-47, 2003 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-14615454
5.
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
Clin Cancer Res
; 9(3): 1136-44, 2003 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-12631619
6.
A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma.
Clin Lymphoma
; 4(2): 119-22, 2003 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-14556685
7.
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
J Clin Oncol
; 24(6): 937-44, 2006 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-16418495
Resultados
1 -
7
de 7
1
Próxima >
>>